Search Within

Neil Howard Segal

Formats
  1. Meeting Abstract (110)
  2. Journal Article (95)
  3. Review (2)
  4. Book Section (1)
  5. Miscellaneous (1)
  6. Research Letter (1)
Groups
  1. Department of Medicine (210)
  2. Gastrointestinal Oncology Service (210)
  3. Solid Tumor Oncology Division (210)
  4. Center for Pancreatic Cancer Research (97)
  5. Surgery (80)
  6. Survivorship Research (78)

More Groups

People
  1. Leonard Saltz (81)
  2. Andrea Cercek Hanjis (68)
  3. Zsofia Stadler (67)
  4. Martin Weiser (61)
  5. Rona Yaeger (60)
  6. Jinru Shia (55)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (12)
  4. 2022 (14)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (78)
  2. Annals of Oncology (21)
  3. Clinical Cancer Research (9)
  4. Cancer Research (6)
  5. Journal for ImmunoTherapy of Cancer (6)
  6. Modern Pathology (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (83)
  2. Oxford University Press (26)
  3. American Association for Cancer Research (21)
  4. Elsevier Inc. (19)
  5. Nature Publishing Group (10)
  6. Biomed Central Ltd (6)

More Publishers

Results (210)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Kopetz, S.; Kasper, S.; Rivera, F.; Tournigand, C.; Cheng, Y.; Deshpande, P.; D'Alessio, D.; Amirouchene Angelozzi, N.; Bento Pereira da Silva, A.; Segal, N. H.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update
    Meeting Abstract

    Segal, N. H.; Pelster, M.; Girda, E.; Fong, L.; Olszanski, A. J.; Han, H.; Casey, K. A.; Li, S.; Welf, E.; Chen, C. I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Circulating tumor DNA (ctDNA) for response assessment in patients with anal cancer treated with definitive chemoradiation
    Meeting Abstract

    Alvarez, J.; Cercek, A.; Mohan, N.; Cuaron, J. J.; Zinovoy, M.; Reyngold, M.; Yaeger, R.; Hajj, C.; Fanta, C.; Wong, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors: Initial dose-escalation results
    Meeting Abstract

    Johnson, M.; Lakhani, N.; Girda, E.; Olszanski, A.; Fong, L.; Han, H.; Casey, K.; Li, S.; Visich, J.; Skokos, D.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • PD-1 blockade in solid tumors with defects in polymerase epsilon
    Meeting Abstract

    Rousseau, B.; Bieche, I.; Pasmant, E.; Hamzaoui, N.; Leulliot, N.; Michon, L.; de Reynies, A.; Foote, M.; Masliah-Planchon, J.; Svrcek, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Comparison of intratumoral T-cell repertoires in DNA mismatch repair proficient and deficient colon adenocarcinoma
    Meeting Abstract

    Kim, J. K.; Chen, C. T.; Khan, A.; Segal, N.; Stadler, Z.; Shia, J.; Balachandran, V. P.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)
    Meeting Abstract

    Kasper, S.; Segal, N. H.; Rivera, F.; Tournigand, C.; Cheng, Y.; Deshpande, P.; Amirouchene Angelozzi, N.; Amirouchene da Silva, A. P.; St-Pierre, A.; Kopetz, S.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results
    Meeting Abstract

    Zamarin, D.; Odunsi, K.; Zsiros, E.; Slomovitz, B. M.; Pimentel, A.; Duska, L. R.; Reilley, M.; Nemunaitis, J. J.; Hamouda, D. M.; Patel, H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The frequency of second primary malignancies and colonic polyps in Lynch syndrome with MSI tumors following immune checkpoint blockade
    Meeting Abstract

    Harrold, E.; Patel, Z.; Maio, A.; Cercek, A.; Yaeger, R.; Segal, N. H.; Reidy, D. L.; O'Reilly, E. M.; Desai, A. M.; Carlo, M. I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study (daNIS-3) of the antieTGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancer
    Meeting Abstract

    Segal, N.; Rivera, F.; Tournigand, C.; Kasper, S.; Chen, Y.; Deshpande, P.; Messmann, R.; Kopetz, S.
    Annals of Oncology (2022)

    Fulltext@MSK | Save